Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.60 |
| ▸ | ITGAV | P06756 | 20/20 | 0.60 |
| ▸ | ALB | P02768 | 2/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6777530 | 0.82 | ITGB3 (0.68) | ITGB3ITGAVALBITGA2B | |
| SCHEMBL5878358 | 0.78 | ITGB3 (0.72) | ITGB3ITGAVALBITGA2B | |
| SCHEMBL5878281 | 0.78 | ITGB3 (0.65) | ITGB3ITGAVALBITGA2B | |
| SCHEMBL7660387 | 0.78 | ITGB3 (0.65) | ITGB3ITGAVALBITGA2B | |
| SCHEMBL5878216 | 0.76 | ITGB3 (0.75) | ITGB3ITGAVALBITGA2B | |
| SCHEMBL5878224 | 0.76 | ITGB3 (0.75) | ITGB3ITGAVALBITGA2B | |
| SCHEMBL5878269 | 0.76 | ITGB3 (0.69) | ITGB3ITGAVALBITGA2B | |
| SCHEMBL5878507 | 0.75 | ITGB3 (0.75) | ITGB3ITGAVALBITGA2B | |
| SCHEMBL5878484 | 0.75 | ITGB3 (1.00) | ITGB3ITGAVALBITGA2B | |
| SCHEMBL5878487 | 0.75 | ITGB3 (1.00) | ITGB3ITGAVALBITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677360-B2 | TREATMENT AND PROPHYLAXIS OF CANCER, ARTERIOSCLEROSIS, RESTENOSIS, OSTEOPOROSIS AND EYE DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-01-13 | — | — | US | disclosed |
| US-20020016461-A1 | Biphenyl and biphenyl-analogous compounds as integrin antagonists | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016461-A1 | Biphenyl and biphenyl-analogous compounds as integrin antagonists | ITGB1, ITGB2, ITGB3 | ITGB3 3/4885ITGAV 13/4885ALB 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.